Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $115 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Ultragenyx Pharmaceutical (NASDAQ:RARE) and maintained a price target of $115.
June 12, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Ultragenyx Pharmaceutical and maintained a price target of $115, indicating strong confidence in the company's future performance.
The reiteration of an Overweight rating and a maintained price target of $115 by a reputable analyst suggests strong confidence in Ultragenyx Pharmaceutical's future performance. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100